Chinese Biopharma Firm Zai Lab Completes $150M US Listing, Shares Jump 55%

Chinese biopharmaceutical company Zai Lab Ltd., backed by Chinese venture capital firms including Advantech, OrbiMed Asia Partners and Qiming Venture Partners, has completed an initial public offering on the NASDAQ in New York, raising approximately US$150 million in total.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets